{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=briquilimab", "query": { "intervention": "briquilimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T03:24:22.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05357482", "title": "Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Beta Thalassemia" ], "interventions": [ { "name": "TBI", "type": "RADIATION" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "briquilimab", "type": "BIOLOGICAL" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "4 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2022-05-12", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05357482" }, { "nct_id": "NCT06162728", "title": "Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Briquilimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jasper Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2023-11-29", "completion_date": "2026-07-08", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06162728" }, { "nct_id": "NCT05907746", "title": "Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GATA2", "Immunodeficiency" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Post-Transplant Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Briquilimab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "2D echo", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "PFT's", "type": "PROCEDURE" }, { "name": "CT scan of chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "6 Years to 70 Years" }, "enrollment_count": 13, "start_date": "2023-11-29", "completion_date": "2028-07-31", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907746" }, { "nct_id": "NCT05903274", "title": "JSP191 (briquilimab) in Subjects with LR-MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lower-risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "JSP191", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jasper Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-06-19", "completion_date": "2024-10-21", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 2, "location_summary": "Hollywood, Florida • Tampa, Florida", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05903274" }, { "nct_id": "NCT06736262", "title": "A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urticaria Chronic" ], "interventions": [ { "name": "Briquilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jasper Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2024-11-26", "completion_date": "2026-07-21", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06736262" }, { "nct_id": "NCT06145282", "title": "Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Briquilimab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "4 Years to 100 Years" }, "enrollment_count": 6, "start_date": "2023-12-28", "completion_date": "2027-11-26", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06145282" }, { "nct_id": "NCT04784052", "title": "Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia" ], "interventions": [ { "name": "JSP191", "type": "DRUG" }, { "name": "CliniMACS Prodigy System", "type": "DEVICE" }, { "name": "Depleted Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Rabbit Anti-Thymoglobulin (rATG)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL" ], "sponsor": "Porteus, Matthew, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 18, "start_date": "2021-12-07", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-04T03:24:22.864Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04784052" } ] }